 Jeffrey Kern
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 26 | 2025 | 2637 | 2.330 |
Why?
| | Neuregulin-1 | 9 | 2019 | 49 | 2.230 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 18 | 2025 | 1180 | 1.690 |
Why?
| | Lung | 13 | 2019 | 4109 | 1.360 |
Why?
| | Signal Transduction | 10 | 2019 | 5226 | 1.040 |
Why?
| | Respiratory Mucosa | 4 | 2014 | 322 | 0.980 |
Why?
| | Radiosurgery | 3 | 2025 | 400 | 0.940 |
Why?
| | Pneumonectomy | 2 | 2025 | 169 | 0.930 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2022 | 199 | 0.860 |
Why?
| | Acute Lung Injury | 3 | 2012 | 303 | 0.830 |
Why?
| | ErbB Receptors | 7 | 2014 | 627 | 0.730 |
Why?
| | Receptor, ErbB-3 | 6 | 2007 | 48 | 0.640 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2019 | 433 | 0.630 |
Why?
| | Epithelium | 2 | 2019 | 314 | 0.630 |
Why?
| | Adult Stem Cells | 1 | 2019 | 39 | 0.600 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2020 | 119 | 0.570 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 120 | 0.560 |
Why?
| | Neuroendocrine Cells | 2 | 2016 | 33 | 0.550 |
Why?
| | Adenocarcinoma | 5 | 2019 | 928 | 0.540 |
Why?
| | Neoplasm Staging | 9 | 2025 | 1462 | 0.530 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 339 | 0.510 |
Why?
| | Immunotherapy | 2 | 2022 | 653 | 0.510 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 442 | 0.490 |
Why?
| | Tomography, X-Ray Computed | 7 | 2015 | 2730 | 0.470 |
Why?
| | STAT3 Transcription Factor | 5 | 2009 | 207 | 0.450 |
Why?
| | Interleukin-6 | 1 | 2019 | 780 | 0.430 |
Why?
| | Adherens Junctions | 1 | 2014 | 24 | 0.430 |
Why?
| | B-Lymphocyte Subsets | 1 | 2014 | 80 | 0.400 |
Why?
| | Immunity, Humoral | 1 | 2014 | 120 | 0.390 |
Why?
| | Cell Adhesion | 1 | 2014 | 455 | 0.380 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2019 | 641 | 0.370 |
Why?
| | beta Catenin | 1 | 2014 | 252 | 0.370 |
Why?
| | Pulmonary Fibrosis | 2 | 2007 | 395 | 0.360 |
Why?
| | Epithelial Cells | 3 | 2011 | 1125 | 0.360 |
Why?
| | Blood Coagulation Factors | 1 | 2012 | 55 | 0.360 |
Why?
| | Protein C | 1 | 2012 | 53 | 0.360 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 20 | 0.360 |
Why?
| | Quality of Life | 1 | 2024 | 3185 | 0.340 |
Why?
| | Smad3 Protein | 1 | 2011 | 43 | 0.340 |
Why?
| | Smad2 Protein | 1 | 2011 | 37 | 0.340 |
Why?
| | Trans-Activators | 2 | 2004 | 405 | 0.330 |
Why?
| | Receptors, Cell Surface | 1 | 2012 | 377 | 0.310 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 266 | 0.310 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 178 | 0.310 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2012 | 636 | 0.300 |
Why?
| | Neoplasms | 3 | 2024 | 2875 | 0.300 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2011 | 219 | 0.290 |
Why?
| | Lung Diseases | 2 | 2016 | 787 | 0.290 |
Why?
| | Permeability | 4 | 2014 | 168 | 0.280 |
Why?
| | Humans | 47 | 2025 | 144759 | 0.280 |
Why?
| | Quinazolines | 5 | 2014 | 266 | 0.280 |
Why?
| | Phosphorylation | 6 | 2019 | 1732 | 0.280 |
Why?
| | Prenylation | 1 | 2008 | 3 | 0.270 |
Why?
| | Early Detection of Cancer | 1 | 2013 | 463 | 0.270 |
Why?
| | Antibodies, Monoclonal | 5 | 2007 | 1519 | 0.260 |
Why?
| | Piperidines | 1 | 2008 | 217 | 0.240 |
Why?
| | Tomography, Emission-Computed | 2 | 2003 | 71 | 0.230 |
Why?
| | DNA-Binding Proteins | 2 | 2004 | 1499 | 0.230 |
Why?
| | Protein Kinase Inhibitors | 4 | 2014 | 969 | 0.230 |
Why?
| | Epidermal Growth Factor | 3 | 2012 | 171 | 0.220 |
Why?
| | Drug Eruptions | 2 | 2024 | 28 | 0.210 |
Why?
| | Autocrine Communication | 1 | 2004 | 38 | 0.210 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2024 | 48 | 0.200 |
Why?
| | Morphogenesis | 1 | 2004 | 173 | 0.200 |
Why?
| | Enzyme Inhibitors | 2 | 2004 | 824 | 0.200 |
Why?
| | Pyridines | 1 | 2008 | 605 | 0.200 |
Why?
| | Mediastinal Neoplasms | 1 | 2003 | 51 | 0.200 |
Why?
| | Skin Diseases | 2 | 2024 | 149 | 0.190 |
Why?
| | Mass Screening | 1 | 2012 | 1347 | 0.190 |
Why?
| | Aged, 80 and over | 9 | 2025 | 8265 | 0.190 |
Why?
| | Genetic Therapy | 1 | 2005 | 313 | 0.190 |
Why?
| | Milk Proteins | 1 | 2002 | 35 | 0.190 |
Why?
| | Cell Line, Tumor | 6 | 2019 | 3540 | 0.190 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 380 | 0.180 |
Why?
| | Clinical Decision-Making | 1 | 2025 | 359 | 0.180 |
Why?
| | Cell Line | 4 | 2014 | 2882 | 0.180 |
Why?
| | Cisplatin | 2 | 2020 | 334 | 0.180 |
Why?
| | ADAM17 Protein | 2 | 2012 | 42 | 0.180 |
Why?
| | Cell Proliferation | 4 | 2015 | 2496 | 0.170 |
Why?
| | ADAM Proteins | 2 | 2012 | 63 | 0.170 |
Why?
| | Radiopharmaceuticals | 1 | 2002 | 194 | 0.170 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2002 | 156 | 0.170 |
Why?
| | RNA Interference | 2 | 2014 | 476 | 0.170 |
Why?
| | Animals | 10 | 2021 | 38058 | 0.170 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 104 | 0.160 |
Why?
| | Recombinant Proteins | 3 | 2011 | 1370 | 0.160 |
Why?
| | Etoposide | 1 | 2020 | 166 | 0.160 |
Why?
| | Female | 16 | 2025 | 78271 | 0.150 |
Why?
| | Enzyme Induction | 1 | 2019 | 88 | 0.150 |
Why?
| | Tight Junctions | 2 | 2014 | 81 | 0.150 |
Why?
| | RNA, Neoplasm | 1 | 2019 | 86 | 0.150 |
Why?
| | Antigens | 1 | 2021 | 347 | 0.150 |
Why?
| | Receptors, Interleukin-6 | 1 | 2019 | 47 | 0.150 |
Why?
| | Cells, Cultured | 3 | 2019 | 4154 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 264 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 241 | 0.140 |
Why?
| | Enzyme Activation | 2 | 2014 | 766 | 0.140 |
Why?
| | Sirolimus | 1 | 2020 | 281 | 0.140 |
Why?
| | Transfection | 3 | 2011 | 940 | 0.140 |
Why?
| | Decision Making | 1 | 2025 | 975 | 0.140 |
Why?
| | Male | 15 | 2025 | 72315 | 0.140 |
Why?
| | Hyperplasia | 2 | 2016 | 174 | 0.130 |
Why?
| | Middle Aged | 10 | 2025 | 35875 | 0.130 |
Why?
| | Aged | 9 | 2025 | 25913 | 0.130 |
Why?
| | Cell Lineage | 1 | 2019 | 376 | 0.130 |
Why?
| | Mice | 6 | 2019 | 18339 | 0.130 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 928 | 0.130 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2020 | 449 | 0.120 |
Why?
| | RNA, Messenger | 3 | 2019 | 2832 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2021 | 846 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2017 | 205 | 0.120 |
Why?
| | Cytokines | 1 | 2024 | 2061 | 0.120 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2947 | 0.120 |
Why?
| | Lung Diseases, Obstructive | 1 | 2016 | 43 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 154 | 0.120 |
Why?
| | Tumor Cells, Cultured | 4 | 2013 | 919 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 983 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 412 | 0.110 |
Why?
| | Research Report | 1 | 2016 | 87 | 0.110 |
Why?
| | Mutation | 4 | 2014 | 4089 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2024 | 11679 | 0.110 |
Why?
| | Drug Synergism | 2 | 2008 | 357 | 0.110 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2015 | 21 | 0.110 |
Why?
| | Bleomycin | 2 | 2007 | 253 | 0.110 |
Why?
| | Electric Impedance | 1 | 2014 | 111 | 0.100 |
Why?
| | ral GTP-Binding Proteins | 1 | 2013 | 5 | 0.100 |
Why?
| | Bronchiolitis | 1 | 2015 | 87 | 0.100 |
Why?
| | Tyrphostins | 2 | 2004 | 18 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 449 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 1045 | 0.090 |
Why?
| | ras Proteins | 1 | 2013 | 150 | 0.090 |
Why?
| | Medical Oncology | 1 | 2016 | 332 | 0.090 |
Why?
| | Protein Binding | 1 | 2019 | 2273 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1982 | 0.090 |
Why?
| | Blotting, Western | 3 | 2013 | 1187 | 0.090 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 171 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 635 | 0.090 |
Why?
| | Time Factors | 3 | 2011 | 7173 | 0.090 |
Why?
| | History, 20th Century | 1 | 2013 | 325 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2017 | 876 | 0.090 |
Why?
| | Tomography, Spiral Computed | 1 | 2011 | 30 | 0.090 |
Why?
| | Prognosis | 6 | 2025 | 4282 | 0.090 |
Why?
| | Cell Division | 2 | 2004 | 766 | 0.090 |
Why?
| | Cell Shape | 1 | 2011 | 57 | 0.080 |
Why?
| | Biopsy, Needle | 1 | 2011 | 183 | 0.080 |
Why?
| | Blood-Air Barrier | 1 | 2011 | 12 | 0.080 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 161 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1129 | 0.080 |
Why?
| | Fibronectins | 1 | 2011 | 136 | 0.080 |
Why?
| | Bronchoscopy | 1 | 2011 | 227 | 0.080 |
Why?
| | Collagen Type I | 1 | 2011 | 147 | 0.080 |
Why?
| | Asthma | 1 | 2022 | 1767 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 623 | 0.080 |
Why?
| | Survival Rate | 4 | 2013 | 2089 | 0.080 |
Why?
| | Protein Inhibitors of Activated STAT | 1 | 2009 | 6 | 0.080 |
Why?
| | Cellular Senescence | 1 | 2012 | 226 | 0.080 |
Why?
| | Vena Cava, Superior | 1 | 2009 | 25 | 0.080 |
Why?
| | Cadherins | 1 | 2011 | 201 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2012 | 383 | 0.070 |
Why?
| | Coronary Vessel Anomalies | 1 | 2009 | 38 | 0.070 |
Why?
| | Transcriptional Activation | 1 | 2011 | 383 | 0.070 |
Why?
| | Interleukin-1beta | 1 | 2011 | 395 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2016 | 947 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2011 | 4557 | 0.070 |
Why?
| | Global Health | 1 | 2011 | 401 | 0.070 |
Why?
| | Dibenzocycloheptenes | 1 | 2008 | 5 | 0.070 |
Why?
| | Colorimetry | 1 | 2008 | 12 | 0.070 |
Why?
| | Prospective Studies | 4 | 2025 | 7990 | 0.070 |
Why?
| | Oncogene Protein v-akt | 1 | 2008 | 22 | 0.070 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 73 | 0.070 |
Why?
| | Antigens, CD | 1 | 2011 | 555 | 0.070 |
Why?
| | Indicators and Reagents | 1 | 2008 | 106 | 0.070 |
Why?
| | Molecular Chaperones | 1 | 2009 | 200 | 0.070 |
Why?
| | Occupational Exposure | 1 | 2011 | 354 | 0.070 |
Why?
| | Abnormalities, Multiple | 1 | 2009 | 197 | 0.070 |
Why?
| | Mesothelioma | 1 | 2008 | 48 | 0.070 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 105 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1173 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2012 | 920 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2012 | 708 | 0.060 |
Why?
| | Azacitidine | 1 | 2008 | 156 | 0.060 |
Why?
| | Comorbidity | 1 | 2011 | 1658 | 0.060 |
Why?
| | Contrast Media | 1 | 2009 | 488 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2006 | 276 | 0.060 |
Why?
| | Nitrates | 1 | 2006 | 100 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1720 | 0.060 |
Why?
| | Lymphatic Metastasis | 2 | 2003 | 333 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2009 | 1455 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2012 | 1339 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2007 | 5992 | 0.060 |
Why?
| | Biomarkers | 2 | 2017 | 4271 | 0.060 |
Why?
| | Collagen | 1 | 2007 | 456 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2012 | 3604 | 0.050 |
Why?
| | Organ Culture Techniques | 1 | 2004 | 154 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1953 | 0.050 |
Why?
| | Pruritus | 1 | 2024 | 59 | 0.050 |
Why?
| | Survival Analysis | 2 | 2005 | 1382 | 0.050 |
Why?
| | Adult | 7 | 2024 | 40449 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2004 | 91 | 0.050 |
Why?
| | Flavonoids | 1 | 2004 | 87 | 0.050 |
Why?
| | Flow Cytometry | 1 | 2008 | 1173 | 0.050 |
Why?
| | Eczema | 1 | 2024 | 66 | 0.050 |
Why?
| | Apoptosis | 2 | 2013 | 2430 | 0.050 |
Why?
| | Exanthema | 1 | 2024 | 84 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 1 | 2003 | 68 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2006 | 477 | 0.050 |
Why?
| | Psoriasis | 1 | 2024 | 112 | 0.050 |
Why?
| | Drug Combinations | 1 | 2004 | 390 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1627 | 0.050 |
Why?
| | Base Sequence | 1 | 2006 | 2190 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2005 | 2115 | 0.050 |
Why?
| | Janus Kinase 3 | 1 | 2002 | 19 | 0.050 |
Why?
| | DNA Methylation | 1 | 2008 | 681 | 0.050 |
Why?
| | STAT6 Transcription Factor | 1 | 2002 | 24 | 0.050 |
Why?
| | Janus Kinase 1 | 1 | 2002 | 26 | 0.050 |
Why?
| | Histoplasmosis | 1 | 2002 | 15 | 0.050 |
Why?
| | Iowa | 1 | 2002 | 32 | 0.050 |
Why?
| | STAT5 Transcription Factor | 1 | 2002 | 52 | 0.050 |
Why?
| | Endosonography | 1 | 2003 | 157 | 0.050 |
Why?
| | Lymph Nodes | 2 | 2002 | 502 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 38 | 0.050 |
Why?
| | Antineoplastic Agents | 2 | 2005 | 2194 | 0.040 |
Why?
| | Cell Polarity | 1 | 2003 | 137 | 0.040 |
Why?
| | Genes, p53 | 1 | 2002 | 67 | 0.040 |
Why?
| | Tyrosine | 1 | 2002 | 222 | 0.040 |
Why?
| | Biopsy | 3 | 2016 | 1075 | 0.040 |
Why?
| | Heart Defects, Congenital | 1 | 2009 | 914 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 688 | 0.040 |
Why?
| | Protein Transport | 1 | 2002 | 441 | 0.040 |
Why?
| | Inflammation | 1 | 2012 | 2878 | 0.040 |
Why?
| | Steroids | 1 | 2021 | 160 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 366 | 0.040 |
Why?
| | United States | 2 | 2022 | 15966 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2005 | 2182 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2006 | 1313 | 0.040 |
Why?
| | Skin | 1 | 2024 | 755 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2002 | 618 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2021 | 255 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2014 | 881 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 1489 | 0.030 |
Why?
| | DNA | 1 | 2004 | 1463 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2017 | 164 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 1985 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 160 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2015 | 17066 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 322 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5408 | 0.030 |
Why?
| | Disease Progression | 2 | 2016 | 2847 | 0.030 |
Why?
| | Prevalence | 1 | 2002 | 2834 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 200 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 1126 | 0.020 |
Why?
| | Aniline Compounds | 1 | 2014 | 119 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2017 | 732 | 0.020 |
Why?
| | Nitriles | 1 | 2014 | 205 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 341 | 0.020 |
Why?
| | Quinolines | 1 | 2014 | 193 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 253 | 0.020 |
Why?
| | Protein Kinases | 1 | 2014 | 315 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 682 | 0.020 |
Why?
| | Sequence Analysis, RNA | 1 | 2014 | 442 | 0.020 |
Why?
| | Pregnancy | 1 | 2004 | 7190 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1813 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 87 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2009 | 151 | 0.020 |
Why?
| | Computational Biology | 1 | 2014 | 680 | 0.020 |
Why?
| | Communication | 1 | 2016 | 965 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2003 | 1716 | 0.020 |
Why?
| | Angiography | 1 | 2009 | 208 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 307 | 0.020 |
Why?
| | Plasmids | 1 | 2009 | 379 | 0.020 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2007 | 53 | 0.020 |
Why?
| | Registries | 1 | 2016 | 2385 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 851 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 570 | 0.020 |
Why?
| | Echocardiography | 1 | 2009 | 652 | 0.010 |
Why?
| | Mediastinoscopy | 1 | 2005 | 5 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1054 | 0.010 |
Why?
| | Trastuzumab | 1 | 2005 | 118 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2006 | 965 | 0.010 |
Why?
| | Electric Conductivity | 1 | 2003 | 84 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2006 | 1539 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2009 | 1496 | 0.010 |
Why?
| | Infant | 1 | 2016 | 10034 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1199 | 0.010 |
Why?
| | Immunoassay | 1 | 2002 | 109 | 0.010 |
Why?
| | Trachea | 1 | 2003 | 261 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 673 | 0.010 |
Why?
| | Risk Assessment | 1 | 2009 | 3671 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2005 | 985 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2003 | 2527 | 0.010 |
Why?
| | Calcium | 1 | 2003 | 1183 | 0.010 |
Why?
| | Wounds and Injuries | 1 | 2003 | 956 | 0.010 |
Why?
| | Rats | 1 | 2003 | 5597 | 0.010 |
Why?
|
|
Kern's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|